

=> d l1; d his; log y  
L1 HAS NO ANSWERS  
L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 15:40:12 ON 23 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:40:32 ON 23 JUL 2003

L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 7 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:41:11 ON 23 JUL 2003

L4 3 S L3

FILE 'BEILSTEIN' ENTERED AT 15:41:47 ON 23 JUL 2003



L5 2 S L1 FUL  
L6 2 S L5 NOT L4

FILE 'MARPAT' ENTERED AT 15:42:32 ON 23 JUL 2003

L7 0 S L1  
L8 2 S L1 FUL  
L9 0 S L8 NOT L4


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	104.55	325.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-1.95

STN INTERNATIONAL LOGOFF AT 15:43:08 ON 23 JUL 2003



L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2002:487542 CAPLUS  
 DN 137:63247  
 TI Preparation of quaternized N-aminoalkyldioxobenzothiazine-3-carboxamides  
 for treatment of cartilage disorders  
 IN Madelmont, Jean-Claude; Giraud, Isabelle; Vidal, Aurelien; Mounetou,  
 Emmanuelle; Rapp, Maryse; Maurizis, Jean-Claude; Renard, Pierre;  
 Caignard, Daniel-Henri; Bizot-Espiard, Jean-Guy  
 PA Les Laboratoires Servier, Fr.; Institut National De La Recherche  
 Medicale  
 SO PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050049	A1	20020627	WO 2001-FR4135	20011221
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
	FR 2818641	A1	20020628	FR 2000-16739	20001221
	AU 2002028120	A5	20020701	AU 2002-28120	20011221
PRAI	FR 2000-16739	A	20001221		
	WO 2001-FR4135	W	20011221		
OS	CASREACT 137:63247; MARPAT 137:63247				
GI					




AB Title compds. [(un)substituted I; R = NHZNR5R6R7X; R1 = H, OH, alkoxy, etc.; R2 = H or alkyl; R5-R7 = alkyl or 2 of R5-R7 = atoms to complete a ring and the other = alkyl; X = halo; Z = alkylene; dashed line = optional addnl. bond] were prepd. Thus, I (R1 = OH, R2 = Me) (II; R = OMe) was amidated by H2N(CH2)3NEt2 and the product quaternized to give II [R = NH(CH2)3NMeEt2I]. Data for biol. activity of I were given.

IT **439254-42-9P 439254-44-1P 439254-46-3P**  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of quaternized N-aminoalkyldioxobenzothiazine-3-carboxamides for treatment of cartilage disorders)

RN 439254-42-9 CAPLUS


CN 1-Propanaminium, N,N-diethyl-3-[[[4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-N-methyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RN 439254-44-1 CAPLUS


CN 1-Propanaminium, N,N,N-triethyl-3-[[ (4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RN 439254-46-3 CAPLUS

CN 1-Butanaminium, 4-[[ (4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

App's

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 2001:12454 CAPLUS  
DN 134:71584  
TI Novel quaternary ammonium derivatives, method for preparing same and pharmaceutical use for treatment or diagnosis of pathologies affecting cartilage  
IN Madelmont, Jean-claude; Giraud, Isabelle; Nicolas, Colette; Maurizis, Jean-claude; Rapp, Maryse; Ollier, Monique; Renard, Pierre; Caignard, Daniel-henri  
PA Adir Et Compagnie, Fr.  
SO PCT Int. Appl., 34 pp.  
CODEN: PIXXD2  
DT Patent  
LA French  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001000621	A1	20010104	WO 2000-FR1731	20000622
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	FR 2795412	A1	20001229	FR 1999-8020	19990623
	FR 2795412	B1	20010713		
	EP 1185526	A1	20020313	EP 2000-945979	20000622
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000011943	A	20020514	BR 2000-11943	20000622
	JP 2003503407	T2	20030128	JP 2001-507029	20000622
	NO 2001006267	A	20020130	NO 2001-6267	20011220
PRAI	FR 1999-8020	A	19990623		
	WO 2000-FR1731	W	20000622		

OS MARPAT 134:71584

AB The invention concerns compds.  $[M-(X)_n-N+R_1R_2R_3]Hal-$  (Ia) wherein M = a mol. for use in the treatment or diagnosis of pathologies affecting cartilage; R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> = alkyl group, or R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> together with the N atom which bears them form a heterocycle; X = C<sub>1</sub>-C<sub>6</sub> alkyl chain wherein one or several -CH<sub>2</sub>- groups are optionally substituted by S, O, -NR, -CO-, -CO-NH-, -CO<sub>2</sub>-, SO- or SO<sub>2</sub>- group; n = 0 or 1; Hal- = halide, or  $[(A)(B)(C)N+R_4]Hal-$  (Ib) in which R<sub>4</sub> = linear or branched C<sub>1</sub>-6 alkyl groups, Hal- = halide, and general formula (A)(B)(C)N (F1) represents a mol. for use in the treatment or diagnosis of pathologies affecting cartilage, provided that the N atom can optionally be included in a satd. or unsatd. nitrogenous heterocyclic system, or involved in a double bond. Pathologies of cartilage affected by treatment with compds. Ia and Ib may include use as anti-inflammatories, analgesics, anti-osteoarthritics, antiarthritics, and antitumor agents. More specific structures for  $[M-(X)_n-N+R_1R_2R_3]Hal-$  (Ia) are also claimed where M = derivs. of Tenidap, Melphalan, Chlorambucil, or glucosamine, and for structure Ib which includes Piroxicam derivs. A dioxotechnetium complex of a 1,4,7,10,13-pentaazacyclopentadecane deriv. is also claimed and a prepn. is given. Processes for the prepn. of the compds. are also claimed and


example prepn. are provided, e.g., via a peptide coupling reaction.

IT 256419-19-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and use of quaternary ammonium halides for treatment or diagnosis of pathologies affecting cartilage, and biodistribution in rat)

RN 256419-19-9 CAPLUS

CN 1-Propanaminium, 3-[[ (4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl) carbonyl] amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)




● I<sup>-</sup>

IT 256419-17-7P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and use of quaternary ammonium halides for treatment or diagnosis of pathologies affecting cartilage, and biodistribution in rat)

RN 256419-17-7 CAPLUS

CN Pyridinium, 2-[[ (4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl) carbonyl] amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1999:757962 CAPLUS

DN 132:117300

TI New Quaternary Ammonium Oxicam Derivatives Targeted toward Cartilage: Synthesis, Pharmacokinetic Studies, and Antiinflammatory Potency

AU Nicolas, Colette; Verny, Michel; Giraud, Isabelle; Ollier, Monique; Rapp, Maryse; Maurizis, Jean-Claude; Madelmont, Jean-Claude

CS INSERM Unite 484, Clermont-Ferrand, 63005, Fr.

SO Journal of Medicinal Chemistry (1999), 42(25), 5235-5240

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English


AB Analogs of nonsteroidal antiinflammatory drugs (NSAIDs) oxicams, in which the active group was linked to a quaternary ammonium function [(4-hydroxy-2-methyl-2H-1,2-benzothiazine-1,1-dioxide-3-carboxamido)2-methylpyridinium iodide or piroxicam-N<sup>+</sup> and [3-(4-hydroxy-2-methyl-2H-1,2-benzothiazine-1,1-dioxide-3-carboxamido)propyl]trimethylammonium iodide or propoxicam-N<sup>+</sup>] were synthesized. Compds. were labeled with tritium for piroxicam-N<sup>+</sup> and carbon-14 for propoxicam-N<sup>+</sup>. Pharmacokinetic studies conducted on rats showed that these mols. were able to highly conc. in joint cartilages but their bioavailability by the oral route was low. Only propoxicam-N<sup>+</sup> exhibited a sufficient water soly. to be administered i.v. This mol. was able to restore proteoglycans biosynthesis in cultured articular chondrocytes treated with Interleukin-1.β. with an efficiency identical to that of indomethacin. These results suggest that the functionalization of oxcam derivs. by a quaternary ammonium group greatly increases their affinity toward articular cartilage without eliminating their pharmacol. activity. New drugs synthesized according to this scheme could be useful to obtain a significant decrease of the efficient administered dose and consequently an attenuation of adverse effects such as digestive toxicity.

IT 256419-17-7 256419-19-9

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses) (new quaternary ammonium oxcam derivs. targeted toward cartilage in relation to synthesis and pharmacokinetic studies and antiinflammatory potency detd. as inhibition of proteoglycan synthesis)

RN 256419-17-7 CAPLUS

CN Pyridinium, 2-[[[4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)




● I<sup>-</sup>

RN 256419-19-9 CAPLUS

CN 1-Propanaminium, 3-[[[4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl]amino]-N,N,N-trimethyl-, iodide (9CI) (CA

INDEX NAME)




● I<sup>-</sup>

IT 256419-26-8P 256419-32-6P

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process) (new quaternary ammonium oxycam derivs. targeted toward cartilage in relation to synthesis and pharmacokinetic studies and antiinflammatory potency detd. as inhibition of proteoglycan synthesis)

RN 256419-26-8 CAPLUS


CN Pyridinium, 2-[[[4-hydroxy-2-(methyl-t3)-1,1-dioxido-2H-1,2-benzothiazin-3-yl]carbonyl]amino]-1-methyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RN 256419-32-6 CAPLUS


CN 1-Propanaminium, 3-[[[4-hydroxy-2-methyl-1,1-dioxido-2H-1,2-benzothiazin-3-yl)carbonyl-14C]amino]-N,N,N-trimethyl-, iodide (9CI) (CA INDEX NAME)



● I<sup>-</sup>

RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT






CM 2

FBRN 3587184

FMF I

Reference(s):

1. Nicolas, Colette; Verny, Michel; Giraud, Isabelle; Ollier, Monique; Rapp, Maryse; Maurizis, Jean-Claude; Madelmont, Jean-Claude, J.Med.Chem., CODEN: JMCMAR, 42(25), <1999>, 5235 - 5240; BABS-6228165




Reference(s):

1. Reymond, Frederic; Steyaert, Guillaume; Pagliara, Alessandra; Carrupt, Pierre-Alain; Testa, Bernard; Girault, Hubert, *Helv.Chim.Acta*, CODEN: HCACAV, 79(6), <1996>, 1651-1669; BABS-6020103

QD1.44


L5 ANSWER 1 OF 1 MARPAT COPYRIGHT 2003 ACS on STN  
 AN 137:63247 MARPAT  
 TI Preparation of quaternized N-aminoalkyldioxobenzothiazine-3-carboxamides  
 for treatment of cartilage disorders  
 IN Madelmont, Jean-Claude; Giraud, Isabelle; Vidal, Aurelien; Mounetou,  
 Emmanuelle; Rapp, Maryse; Maurizis, Jean-Claude; Renard, Pierre;  
 Caignard, Daniel-Henri; Bizot-Espiard, Jean-Guy  
 PA Les Laboratoires Servier, Fr.; Institut National De La Recherche  
 Medicale  
 SO PCT Int. Appl., 38 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050049	A1	20020627	WO 2001-FR4135	20011221
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
	FR 2818641	A1	20020628	FR 2000-16739	20001221
	AU 2002028120	A5	20020701	AU 2002-28120	20011221
PRAI	FR 2000-16739		20001221		
	WO 2001-FR4135		20011221		
OS	CASREACT 137:63247				
GI					




AB Title compds. [(un)substituted I; R = NHZNR5R6R7X; R1 = H, OH, alkoxy,  
 etc.; R2 = H or alkyl; R5-R7 = alkyl or 2 of R5-R7 = atoms to complete a  
 ring and the other = alkyl; X = halo; Z = alkylene; dashed line =  
 optional addnl. bond] were prepd. Thus, I (R1 = OH, R2 = Me) (II; R =  
 OMe) was amidated by H2N(CH2)3NEt2 and the product quaternized to give  
 II [R = NH(CH2)3NMeEt2I]. Data for biol. activity of I were given.

#### MSTR 1



G3 = OH  
 G6 = alkylene<(1-6)>  
 G7 = 26



G8 = alkyl<(1-6)>

G10 = alkyl<(1-6)>

MPL: claim 1

NTE: substitution is restricted

STE: and isomers

RE.CNT 9      THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l1; d his; log y  
L1 HAS NO ANSWERS  
L1 STR

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 15:36:29 ON 23 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:36:36 ON 23 JUL 2003

L1 STRUCTURE UPLOADED  
L2 0 S L1  
L3 0 S L1 FUL


FILE 'MARPAT' ENTERED AT 15:37:02 ON 23 JUL 2003

L4 0 S L1  
L5 1 S L1 FUL


COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	108.78	257.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.62	-0.62

STN INTERNATIONAL LOGOFF AT 15:37:46 ON 23 JUL 2003


L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2003:26751 CAPLUS  
 DN 138:368857  
 TI Synthesis of 3-aminohydantoinyl-1,2-benzothiazine derivatives  
 AU Park, Myung-Sook; Chang, Eun-Sung; Lee, Myung-Sook; Kwon, Soon-Kyoung  
 CS College of Pharmacy, Duksung Women's University, Seoul, 132-714, S. Korea  
 SO Bulletin of the Korean Chemical Society (2002), 23(12), 1836-1838  
 CODEN: BKCSDE; ISSN: 0253-2964  
 PB Korean Chemical Society  
 DT Journal  
 LA English  
 GI



I



II



III

AB N-dioxoimidazolidinyl hydroxybenzothiazinecarboxamides I (R = EtCH<sub>2</sub>, Bu, Me<sub>2</sub>CH, Me<sub>2</sub>CHCH<sub>2</sub>; R<sub>1</sub> = H, Br, Cl) are prepd. as potential analgesic and antiinflammatory agents. 5-Substituted 3-aminoimidazolidinediones (3-aminohydantoin) are prepd. by cyclocondensation of L-amino acids and tert-Bu carbazate in quinoline. Alkylation of the sodium salts of saccharins II (R<sub>1</sub> = H, Br, Cl) with Me chloroacetate followed by ring expansion in the presence of sodium methoxide in methanol gives dioxobenzothiazinecarboxylates III (R<sub>1</sub> = H, Br, Cl). Amidation of III (R<sub>1</sub> = H, Br, Cl) with 5-substituted 3-aminohydantoin provides the title compds. I (R = EtCH<sub>2</sub>, Bu, Me<sub>2</sub>CH, Me<sub>2</sub>CHCH<sub>2</sub>; R<sub>1</sub> = H, Br, Cl) in three steps from saccharins II. I (R = EtCH<sub>2</sub>, Bu, Me<sub>2</sub>CH, Me<sub>2</sub>CHCH<sub>2</sub>; R<sub>1</sub> = H, Br, Cl) show analgesic and antiinflammatory activities (no data).


IT 524707-42-4P 524707-44-6P 524707-46-8P  
 524707-48-0P 524707-50-4P 524707-52-6P  
 524707-54-8P 524707-56-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of N-dioxoimidazolidinyl dioxobenzothiazinecarboxamides from saccharin sodium salts and 3-aminohydantoin and their potential analgesic and antiinflammatory activities)


RN 524707-42-4 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-N-(2,5-dioxo-4-propyl-1-imidazolidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 524707-44-6 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, N-(4-butyl-2,5-dioxo-1-imidazolidinyl)-7-chloro-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 524707-46-8 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-(1-methylethyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 524707-48-0 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-(2-methylpropyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 524707-50-4 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-N-(2,5-dioxo-4-propyl-1-imidazolidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 524707-52-6 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-N-(4-butyl-2,5-dioxo-1-imidazolidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 524707-54-8 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-(1-methylethyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 524707-56-0 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-(2-methylpropyl)-2,5-dioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT




L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 2000:654165 CAPLUS  
 DN 133:358999  
 TI Studies on synthetic 1,2-benzothiazine anti-inflammatory agents: pharmacological effect and the expression of xenobiotic-metabolizing enzymes  
 AU Kim, Sang Geon; Cho, Joo Youn; Kwon, Soon-Kyung; Lee, Eun Bang  
 CS College of Pharmacy, Seoul National University, S. Korea  
 SO Yakhak Hoechi (2000), 44(4), 300-307  
 CODEN: YAHOA3; ISSN: 0513-4234  
 PB Pharmaceutical Society of Korea  
 DT Journal  
 LA Korean  
 AB Expression of xenobiotic-metabolizing enzymes can be altered by xenobiotics, which represent changes in the prodn. of reactive metabolic intermediates as well as toxicities in tissues. Metabolic intermediates derived from xenobiotics are considered to produce the reactive oxygen species including drug free radicals and hydroxyl free radicals, which would be ultimately responsible for drug-induced toxicities. The effects of 1,2-benzothiazine anti-inflammatory agents on the expression of xenobiotic-metabolizing enzymes including major cytochrome P450s, microsomal epoxide hydrolase (mEH) and glutathione S-transferase (GST) were studied in the liver with the aim of providing the part of information on potential prodn. of reactive metabolites and hepatotoxicity by the agents. The synthetic compds. 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (I), 7-bromo-N-[3-(4-chlorophenyl)-4-oxo-2-thioxo-1-imidazolidinyl]-4-hydroxy-2-(2-propenyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide, and 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide (II) exhibited anti-inflammatory effects in rats as assessed by the Randall-Selitto method. The anti-inflammatory effect was detected as early as at 30 min after gavaging the agents with the ED50 being noted at 80 mg/kg, which was comparable to that of ibuprofen. Treatment of rats with each compd. (100 mg/kg, 3d) resulted in no significant induction in the immunochem.-detectable cytochromes P 450 1A1/2, P 450 2B1/2, P 450 2C11 and P 450 2E1. Changes in the mEH expression were also minimal, as evidenced by both Western blot and Northern blot analyses. Hepatic GST expression was slightly increased by the agents: GST Ya protein and mRNA expression was .apprx.1.5-fold increased after treatment with compds. I and II, whereas GST Yb1/2 and Yc1/2 mRNA levels were elevated 2- to 3-fold. In summary, the effects of the synthetic 1,2-benzothiazines on the expression of major P 450, mEH and GST were not significant, providing evidence that metabolic activation of the agents, potential drug interaction and hepatotoxicity would be minimal.  
 IT 183859-52-1 183859-65-6  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study) (effects of benzothiazine anti-inflammatory agents on expression of xenobiotic-metabolizing enzymes)  
 RN 183859-52-1 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-65-6 CAPLUS


CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1999:201272 CAPLUS  
 DN 130:338076  
 TI Synthesis and analgesic and anti-inflammatory activities of  
 1,2-benzothiazine derivatives  
 AU Lee, Eun Bang; Kwon, Soon Kyoung; Kim, Sang Geon  
 CS Natural Products Research Institute, Seoul National University, Seoul,  
 110-460, S. Korea  
 SO Archives of Pharmacal Research (1999), 22(1), 44-47  
 CODEN: APHRDQ; ISSN: 0253-6269  
 PB Pharmaceutical Society of Korea  
 DT Journal  
 LA English  
 GI



AB Three 1,2-benzothiazine derivs. I (R = H, R' = allyl, X = Cl, Br; R = allyl, R' = 4-ClC6H4, X = Br) were synthesized, and their analgesic/anti-inflammatory efficacy and their effects on gastric irritation were evaluated. Among the three compds., I (R = H, R' = allyl, X = Cl) exhibited the most potent analgesic action, but the effect was weaker than that of piroxicam. Nonetheless, the compd. showed 4 times more potent analgesic action with less gastric damage than did ibuprofen. These compds. did not show anti-inflammatory effect at an oral dose of 5 mg/kg.  
 IT **183859-52-1P 183859-65-6P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); BIOL (Biological study); PREP (Preparation) (prepn., analgesic, and anti-inflammatory activity of benzothiazines)  
 RN 183859-52-1 CAPLUS  
 CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-65-6 CAPLUS  
 CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RE.CNT 10      THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1997:55223 CAPLUS  
 DN 126:264061  
 TI Studies on the activities and synthesis of N-substituted pyrimidinyl or triazinyl-3-carbamoyl-4-hydroxy-2H-1,2-benzothiazine-1,1-dioxides  
 AU Zhao, Guo-Feng; Zou, Xiao-Mao; Yang, Hua-Zheng  
 CS Inst. Elemento-Organic Chem. Nankai Univ., Tianjin, 300071, Peop. Rep. China  
 SO Gaodeng Xuexiao Huaxue Xuebao (1996), 17(10), 1560-1564  
 CODEN: KTHPDM; ISSN: 0251-0790  
 PB Gaodeng Jiaoyu Chubanshe  
 DT Journal  
 LA Chinese  
 GI




AB Title compds. I (R = H, Me; R1, R2 = MeO, Cl, Me) were prepd. by aminolysis of 4-hydroxy-2-hydro(methyl)-2H-1,2-benzothiazine-3-carboxylic acid Et ester 1,1-dioxides with substituted aminopyrimidines or aminotriazines. Their structures were characterized by <sup>1</sup>H NMR, IR, MS and elementary anal. The biol. tests indicated that the majority of these compds. showed herbicidal activity and some showed plant-growth regulating activity and antiinflammatory activity.  
 IT **186695-73-8P**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (synthesis and biol. activities of benzothiazine derivs.)  
 RN 186695-73-8 CAPLUS  
 CN 2H-1,2-Benzothiazine-3-carboxamide, N-(4-chloro-6-methoxy-2-pyrimidinyl)-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1996:664323 CAPLUS  
 DN 126:1096  
 TI Some new 1,2-benzothiazine derivatives with analgesic and anti-inflammatory activities  
 AU Kwon, Soon Kyoung; Park, Myung Sook  
 CS College Pharmacy, Duk-Sung Women's University, Seoul, 132-714, S. Korea  
 SO Arzneimittel-Forschung (1996), 46(10), 966-971  
 CODEN: ARZNAD; ISSN: 0004-4172  
 PB Cantor  
 DT Journal  
 LA English  
 AB Twenty-three new 7-halo-4-hydroxy 2H(or alkyl)-N-(3-aralkyl-2-thio-1-hydantoinyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide derivs. were synthesized through the condensation of 7-halo-4-hydroxy-2H(or alkyl)-1,2-benzothiazine-3-carboxylic acid Me ester 1,1-dioxides with 1-amino-2-thio-3-aralkylimidazolidine-4-ones. The analgesic and anti-inflammatory activities of the synthesized compds. were investigated by acetic acid-induced writhing syndrome and carrageenan rat paw edema tests. In analgesic activities most compds. exhibited higher activities than acetylsalicylic acid, but in anti-inflammatory activities most compds. except 3 of them showed lower activities than indomethacin.  
 IT 183859-51-0P 183859-52-1P 183859-54-3P  
 183859-55-4P 183859-64-5P 183859-65-6P  
 183859-66-7P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and analgesic and anti-inflammatory activities of benzothiazine derivs.)  
 RN 183859-51-0 CAPLUS  
 CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-(3-methyl-4-oxo-2-thioxo-1-imidazolidinyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-52-1 CAPLUS  
 CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-54-3 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-N-[3-(4-chlorophenyl)-4-oxo-2-thioxo-1-imidazolidinyl]-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-55-4 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-bromo-4-hydroxy-N-[4-oxo-3-(phenylmethyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-64-5 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-(3-methyl-4-oxo-2-thioxo-1-imidazolidinyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-65-6 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-[4-oxo-3-(2-propenyl)-2-thioxo-1-imidazolidinyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 183859-66-7 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, 7-chloro-4-hydroxy-N-(4-oxo-3-phenyl-2-thioxo-1-imidazolidinyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)





L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1993:449321 CAPLUS  
 DN 119:49321  
 TI The synthesis of 1,2-benzothiazine-3-carboxamidyldhydantoin derivatives and their antiinflammatory and analgesic activities  
 AU Kwon, Soon Kyoung; Park, Myoung Suk  
 CS Coll. Pharm., Duksung Women's Univ., Seoul, 132-714, S. Korea  
 SO Archives of Pharmacal Research (1992), 15(3), 251-5  
 CODEN: APHRDQ; ISSN: 0253-6269  
 DT Journal  
 LA English  
 OS CASREACT 119:49321  
 GI




AB Twenty-one 4-hydroxy-2H (or alkyl)-N-(3-aralkyl-2-thio-1-hydantoinyl)-1,2-benzothiazine-3-carboxamide 1,1-dioxides, e.g., I, were synthesized through the reaction of 4-hydroxy-2H (or alkyl)-1,2-benzothiazine-3-carboxylic Me ester 1,1-dioxides and 1-amino-2-thio-3-aralkyl-4-imidazolones in xylene. The compds. synthesized were screened for antiinflammatory effect on carrageenin-induced edema in rat and for analgesic effect on acetic acid-induced writhing syndrome in mice. Most compds. were inhibitors of carrageenin-induced rat foot edema and some showed significant antiinflammatory activity comparable to that of indomethacin and significant analgesic activity comparable to that of indomethacin and aspirin.

IT **148316-43-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn., antiinflammatory and analgesic activity of)


RN 148316-43-2 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, N-[3-(4-chlorophenyl)-4-oxo-2-thioxo-1-imidazolidinyl]-4-hydroxy-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
 AN 1984:472742 CAPLUS  
 DN 101:72742  
 TI 4-Hydroxy-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide, its use, and  
 pharmaceuticals containing these compounds  
 IN Trummlitz, Guenter; Engel, Wolfhard; Seeger, Ernst; Haarmann, Walter  
 PA Thomae, Dr. Karl, G.m.b.H., Fed. Rep. Ger.  
 SO Ger. Offen., 32 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3237473	A1	19840412	DE 1982-3237473	19821009
	EP 106214	A1	19840425	EP 1983-109512	19830924
	EP 106214	B1	19851204		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	AT 16807	E	19851215	AT 1983-109512	19830924
	US 4533664	A	19850806	US 1983-537592	19830930
	FI 8303566	A	19840410	FI 1983-3566	19831003
	SU 1148565	A3	19850330	SU 1983-3654490	19831005
	DK 8304607	A	19840410	DK 1983-4607	19831006
	DD 215549	A5	19841114	DD 1983-255478	19831006
	NO 8303665	A	19840410	NO 1983-3665	19831007
	AU 8319986	A1	19840412	AU 1983-19986	19831007
	GB 2128190	A1	19840426	GB 1983-26876	19831007
	GB 2128190	B2	19860702		
	JP 59088482	A2	19840522	JP 1983-188284	19831007
	ES 526332	A1	19841116	ES 1983-526332	19831007
	HU 34472	A2	19850328	HU 1983-3482	19831007
	HU 190169	B	19860828		
	CS 236896	B2	19850515	CS 1983-7378	19831007
	ZA 8307500	A	19850626	ZA 1983-7500	19831007
	CA 1207767	A1	19860715	CA 1983-438617	19831007
	PL 139147	B1	19861231	PL 1983-244080	19831007
	IL 69931	A1	19870331	IL 1983-69931	19831007
	ES 531402	A1	19841216	ES 1984-531402	19840409
PRAI	DE 1982-3237473		19821009		
	EP 1983-109512		19830924		
OS	CASREACT 101:72742				
GI					



I


AB The title compds. (I; R = H, Me, MeO, Cl, F; R1 = H, Me, Et, Pr) were  
 prepd. Thus, Me 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate  
 1,1-dioxide was refluxed 24 h in C6H4Me2 with 2-amino-6-chloropyrazine  
 to give 64% I (R = H, R1 = Me) (II). In mice 10 mg II/kg orally  
 increased bleeding time 103%.

IT 91286-70-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);  
 RACT (Reactant or reagent)(prepn., ethylation, and methylation of)

RN 91286-70-3 CAPLUS

CN 2H-1,2-Benzothiazine-3-carboxamide, N-(6-chloropyrazinyl)-4-hydroxy-,  
1,1-dioxide (9CI) (CA INDEX NAME)





L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS on STN  
AN 1975:472175 CAPLUS  
DN 83:72175  
TI Benzothiazine dioxides as antithrombotic agents  
IN Lombardino, Joseph G.; Wiseman, Edward A.  
PA Pfizer, Inc.  
SO U.S., 6 pp.  
CODEN: USXXAM

DT Patent  
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 3862319	A	19750121	US 1973-362518	19730521
PRAI	US 1969-829713		19690602		
	US 1971-114037		19710209		
GI	For diagram(s), see printed CA Issue.				
AB	Comps. of the general structures I and II were effective antithrombotic agents. Physiol. testing data in animals and man was given.				
IT	<b>56209-19-9</b>				
	RL: BIOL (Biological study)				
	(antithrombotic)				
RN	56209-19-9 CAPLUS				
CN	2H-1,2-Benzothiazine-3-carboxamide, N-(5-chloro-2-pyridinyl)-3,4-dihydro-4-hydroxy-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)				






Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214


Beilstein Records (BRN): 7784248  
Molec. Formula (MF): C19 H15 Br N4 O5 S2  
Molecular Weight (MW): 523.38  
Lawson Number (LN): 31458, 28769, 14140  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6631776  
Tautomer ID (TAUTID): 7358730  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214


Beilstein Records (BRN): 7783321  
Molec. Formula (MF): C18 H13 Br N4 O5 S2  
Molecular Weight (MW): 509.35  
Lawson Number (LN): 31458, 28769, 14131  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6629621  
Tautomer ID (TAUTID): 7358136  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

Beilstein Records (BRN): 7783308  
Molec. Formula (MF): C18 H13 Cl N4 O5 S2  
Molecular Weight (MW): 464.90  
Lawson Number (LN): 31458, 28769, 14131  
Compound Type (CTYPE): heterocyclic  
Constitution ID (CONSID): 6628019  
Tautomer ID (TAUTID): 7357920  
Beilstein Citation (BSO): 6-27  
Entry Date (DED): 1998/03/03  
Update Date (DUPD): 1998/03/03




Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214




Beilstein Records (BRN):	7782315
Molec. Formula (MF):	C15 H13 Br N4 O5 S2
Molecular Weight (MW):	473.32
Lawson Number (LN):	31458, 28769, 2947
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6627609
Tautomer ID (TAUTID):	7357341
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214


Beilstein Records (BRN):	7782314
Molec. Formula (MF):	C15 H13 Cl N4 O5 S2
Molecular Weight (MW):	428.86
Lawson Number (LN):	31458, 28769, 2947
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6627686
Tautomer ID (TAUTID):	7357707
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214


Beilstein Records (BRN):	7781525
Molec. Formula (MF):	C13 H11 Br N4 O5 S2
Molecular Weight (MW):	447.28
Lawson Number (LN):	31458, 28769, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6622740
Tautomer ID (TAUTID):	7354727
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214


Beilstein Records (BRN):	7781524
Molec. Formula (MF):	C13 H11 Cl N4 O5 S2
Molecular Weight (MW):	402.83
Lawson Number (LN):	31458, 28769, 2817
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	6621898
Tautomer ID (TAUTID):	7355053
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1998/03/03
Update Date (DUPD):	1998/03/03



Reference(s):

1. Kwon, Soon-Kyoung; Park, Myung-Sook, *Arzneim.Forsch.*, CODEN: ARZNAD, 46(10), <1996>, 966-971; BABS-6061214

=> d l1; d his; log y  
 L1 HAS NO ANSWERS  
 L1 STR



Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 15:19:02 ON 23 JUL 2003)

FILE 'REGISTRY' ENTERED AT 15:19:11 ON 23 JUL 2003

L1 STRUCTURE UPLOADED  
 L2 1 S L1  
 L3 19 S L1 FUL

FILE 'CAPLUS' ENTERED AT 15:19:42 ON 23 JUL 2003

L4 8 S L3

FILE 'BEILSTEIN' ENTERED AT 15:20:28 ON 23 JUL 2003

L5 2 S L1  
 L6 8 S L1 FUL  
 L7 8 S L6 NOT L4  
 L8 8 S L6 NOT L3

FILE 'MARPAT' ENTERED AT 15:21:34 ON 23 JUL 2003

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.40	454.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-5.21

STN INTERNATIONAL LOGOFF AT 15:21:49 ON 23 JUL 2003